- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Cipla Limited — Important, 21-02-2026: Updates
21-02-2026 | 05:52 pm
21-02-2026 | 05:52 pm
Cipla's supply partner, Pharmathen, received an 'Official Action Indicated' (OAI) from USFDA for its Greece facility's manufacturing practices. This regulatory classification signals significant issues, potentially impacting the supply of Lanreotide Injection for Cipla USA.
No comments yet. Be the first to comment!